EGFR inhibitor erlotinib plus monoclonal antibody versus erlotinib alone for first-line treatment of advanced non-small cell lung carcinoma: A systematic review and meta-analysis
Article in International Immunopharmacology (April 2023)
The most recent citing publications are shown below. View all 11 publications that cite this research output on Dimensions.
Article in International Immunopharmacology (April 2023)
Article in International Journal of General Medicine (January 2022)
Article in BMC Complementary Medicine and Therapies (December 2020)